ChemicalBook
Chinese english Germany

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 化学構造式
62013-04-1
CAS番号.
62013-04-1
化学名:
(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン
别名:
ジリスロマイシン;抗生物質AS-E-136;抗生物質AS-E136;(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン;ジリトロマイシン
英語化学名:
Dirithromycin
英語别名:
Dynabac;Valodin;ASE 136;Noriclan;KT 237216;LY-237216;Dirithomycin;DIRITHROMYCIN;Dirythromycin;Antibiotic AS-E 136
CBNumber:
CB1337350
化学式:
C42H78N2O14
分子量:
835.07
MOL File:
62013-04-1.mol

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 物理性質

融点 :
186-189° (dec) (Counter)
貯蔵温度 :
2-8°C
溶解性:
Very slightly soluble in water, very soluble in methanol and in methylene chloride
酸解離定数(Pka):
9.0 in 66% aq dimethyl fluoride
外見 :
solid
色:
white to off-white
CAS データベース:
62013-04-1(CAS DataBase Reference)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xn,Xi
Rフレーズ  42/43-36/37/38
Sフレーズ  36-26
WGK Germany  3
HSコード  29419000
毒性 LD50 in mice (g/kg): >1 s.c.; >1 orally (Maier)
絵表示(GHS)
注意喚起語 Warning
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H317 アレルギー性皮膚反応を起こすおそれ 感作性、皮膚 1 警告 P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
注意書き
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 価格 もっと(12)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01TRCD493000 ジリスロマイシン
Dirithromycin
62013-04-1 5mg ¥11300 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01TRCD493000 ジリスロマイシン
Dirithromycin
62013-04-1 10mg ¥12500 2018-12-26 購入
東京化成工業 D5495 ジリスロマイシン >98.0%(HPLC)(N)
Dirithromycin >98.0%(HPLC)(N)
62013-04-1 1g ¥21800 2018-12-04 購入
Sigma-Aldrich Japan D2880000 European Pharmacopoeia (EP) Reference Standard
Dirithromycin European Pharmacopoeia (EP) Reference Standard
62013-04-1 d2880000 ¥33600 2018-12-25 購入
Sigma-Aldrich Japan 1220700 United States Pharmacopeia (USP) Reference Standard
Dirithromycin United States Pharmacopeia (USP) Reference Standard
62013-04-1 200mg ¥70900 2018-12-25 購入

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン MSDS


[9S(R)]-9-Deoxo-11-deoxy-9,11-[imino[2-(2-methoxy)ethylidene]oxy]erthromycin

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 化学特性,用途語,生産方法

化学的特性

white crystals

使用

antihypertensive

使用

Dirithromycin is a macrolide antibiotic pro-drug of 9S-erythromycylamine, a close analogue of erythromycin in which the 9-keto group is replaced with an amino group in the S-configuration. Although erythromycylamine overcomes the acid instability of erythromycin, it is poorly absorbed following oral administration. Dirithromycin is formed by reacting erythromycylamine with an aldehyde to form a Schiff base which undergoes cyclisation to an oxazine with the C11-alcohol. Dirithromycin provides higher tissue levels and prolonged in vivo half-life by slowly releasing erythromycylamine.

使用

Semi-synthetic derivative of Erythromycin. Antibacterial

定義

ChEBI: The hemi-aminal resulting from the condensation of the erythromycin derivative (9S)-erythromycyclamine with 2-(2-methoxyethoxy)acetaldehyde. As the oxazine ring containing the hemi-aminal group is unstable under both acidic and alkaline co ditions, dirithromycin functions as a more lipid-soluble prodrug for (9S)-erythromycyclamine. Administered as enteric coated tablets to protect it from acid catalysed hydrolysis in the stomach, it is used to treat respiratory tract, skin, nd soft tissue infections caused by susceptible organisms.

brand name

Dynabac (Lilly).

一般的な説明

The incidence and severity of GI adverse effects associatedwith dirithromycin are similar to those seen with oralerythromycin. Preliminary studies indicate that dirithromycinand erythromycyclamine do not interact significantly with cytochromeP450 oxygenases. Thus, the likelihood of interferencein the oxidative metabolism of drugs such as phenytoin,theophylline, and cyclosporine by these enzymes may be lesswith dirithromycin than with erythromycin. Dirithromycin isrecommended as an alternative to erythromycin for the treatmentof bacterial infections of the upper and lower respiratorytracts, such as pharyngitis, tonsillitis, bronchitis, and pneumonia,and for bacterial infections of other soft tissues and theskin. The once-daily dosing schedule for dirithromycin is advantageousin terms of better patient compliance. Its place intherapy remains to be fully assessed.

応用例(製薬)

A prodrug of erythromycylamine, a semisynthetic erythromycin A derivative, formulated for oral administration. Activity against respiratory pathogens is generally poorer than that of erythromycin A.
The long apparent elimination half-life (30–44 h) allows once-daily administration. Around 60–90% of a dose is converted to erythromycylamine within 35 min after intravenous administration. After oral administration of single doses of 500–1000 mg to healthy volunteers, the peak plasma concentrations ranged from 0.29 to 0.64 mg/L after 4–5 h. The absolute bioavailability after oral administration is about 10%. It achieves a higher concentration than erythromycin in some tissues. After a 500 mg single oral dose, the mean peak biliary concentration was 139 mg/L. Renal and non-renal clearance was lower in patients with biliary disease than in other patients or healthy volunteers.
About 60–80% of an oral dose and over 80% of an intravenous dose are eliminated in the feces, predominantly as erythromycylamine. Dosage adjustments do not appear necessary in patients with mild or moderate hepatic, biliary or renal impairment. Negligible amounts of the drug are removed during hemodialysis.
Adverse events are similar to those found with other macrolides. Gastrointestinal events are most common; around 5% of patients experience abdominal pain, diarrhea or nausea.
It has been used in community-acquired infections of the respiratory tract and skin and soft-tissue infections. It is no longer widely available.

(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 上流と下流の製品情報

原材料

準備製品


(9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン 生産企業

Global( 153)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22043 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32651 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2548 55
Hubei Jusheng Technology Co.,Ltd.
86-188-71490254
peter@hubeijusheng.com CHINA 20243 58
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96815 76
Pure Chemistry Scientific Inc. 001-857-928-2050 or 1-888-588-9418
001-617-206-9595 sales@chemreagents.com United States 9943 62
Shanghai Hanhong Scientific Co.,Ltd. 021-54306202,021-54308259
+86-21-54291107 info@hanhonggroup.com China 43389 64
Chemsky(shanghai)International Co.,Ltd. 021-50135380
shchemsky@sina.com China 32492 50
XiaoGan ShenYuan ChemPharm co,ltd Tell:86-712-2580635 Mobile:15527768850 . 15527768836
86-712-2580625 QQ:1623551145 sales02@farchem.com China 9143 52

62013-04-1((9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン)キーワード:


  • 62013-04-1
  • Dynabac
  • KT 237216
  • Noriclan
  • Valodin
  • [9S]-9-Deoxo-11-deoxy-9,11-[imino[2-(2methoxyethoxy)ethylidene]oxy]erythromycin
  • (2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2S,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
  • (9S)-9-Deoxo-11-deoxy-9,11-(imino((1R)-2-(2-methoxyethoxy)ethylidene)oxy)erythromycin
  • (9S)-9-Deoxo-11-deoxy-9,11-[imino[(R)-2-(2-methoxyethoxy)ethane-1,1-diyl]oxy]erythromycin
  • Dirithromycin (200 mg)
  • DirithroMycin/LY-237216
  • 4,16-Dioxa-14-azabicyclo[11.3.1]heptadecan-5-one, 7-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-
  • LY-237216
  • DIRITHROMYCIN
  • [9S(R)]-9-DEOXO-11-DEOXY-9,11-[IMINO[2-(2-METHOXY)ETHYLIDENE]OXY]ERTHROMYCIN
  • [9s(r)]-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxy)ethylidene]oxy]erthromycin,ly-237216
  • Dirithomycin
  • 9-(4-Dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-3-ethyl-2,10-dihydroxy-7-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
  • [9S(R)]-9-Deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]oxy]erythromycin
  • Antibiotic AS-E 136
  • ASE 136
  • Dirythromycin
  • ジリスロマイシン
  • 抗生物質AS-E-136
  • 抗生物質AS-E136
  • (9S)-9-デオキソ-11-デオキシ-9,11-[イミノ[(R)-2-(2-メトキシエトキシ)エタン-1,1-ジイル]オキシ]エリスロマイシン
  • ジリトロマイシン
  • マクロライド系抗生物質
Copyright 2017 © ChemicalBook. All rights reserved